Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.

Rossing, Peter; Strand, Jorma; Avogaro, Angelo; Becka, Michael; Kanefendt, Friederike; Otto, Christiane

Rossing, Peter; Strand, Jorma; Avogaro, Angelo; Becka, Michael; Kanefendt, Friederike; Otto, Christiane.

Affiliation

Rossing P; Steno Diabetes Center Copenhagen, Gentofte and University of Copenhagen, Copenhagen, Denmark.
Strand J; Terveystalo Oulu, Oulu, Finland.
Avogaro A; Department of Medicine, University of Padova, Padova, Italy.
Becka M; Research and Clinical Sciences Statistics, Bayer AG, Wuppertal, Germany.
Kanefendt F; Clinical Pharmacokinetics, Bayer AG, Wuppertal, Germany.
Otto C; Experimental Medicine Cardiovascular, Bayer AG, Wuppertal, Germany.

Nephrol Dial Transplant ; 36(12): 2263-2273, 2021 12 02.

Article de En | MEDLINE | ID: mdl-33367744

Sujet(s)
Mots clés

chymase inhibitor; diabetic kidney disease; fulacimstat

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Diabète de type 2 / Néphropathies diabétiques Type d'étude: Clinical_trials / Etiology_studies / Prognostic_studies Limites: Humans Langue: En Journal: Nephrol Dial Transplant Sujet du journal: NEFROLOGIA / TRANSPLANTE Année: 2021 Type de document: Article Pays d'affiliation: Danemark Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google